Janus Henderson Investors

Portfolio Co Investors 2026 for Janus Henderson Investors: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Janus Henderson Investors accounts for 67 tracked companies with verified cap-table data, 67 of which disclose round sizes totalling $15B. The median disclosed raise is $175M, and the largest is Kymera Therapeutics at $3B, ahead of BioNTech.de ($595M) and Gracell Biotechnologies ($520M).

The names that recur most often on these co-invested cap tables are Janus Henderson Investors (67 companies), RA Capital Management (26 companies), Logos Capital (20 companies), Cormorant Asset Management (15 companies), OrbiMed (14 companies), Surveyor Capital (14 companies). By latest disclosed round, the market skews Series B (24), Series A (15), Series C (14), Growth (7).

Best funded Janus Henderson Investors companies

  1. Kymera Therapeutics — $3B (latest: Series C)
  2. BioNTech.de — $595M (latest: Series B)
  3. Gracell Biotechnologies — $520M (latest: IPO)
  4. Parabilis Medicines — $500M (latest: Series F)
  5. Angitia Biopharmaceuticals — $406M (latest: Series D)
  6. Quell Therapeutics — $344M (latest: Series B)
  7. Kardium — $340M (latest: Growth)
  8. Wallbox — $330M (latest: IPO)
  9. Triveni Bio — $277M (latest: Series C)
  10. NiKang Therapeutics — $260M (latest: Series C)
  11. Diagonal Therapeutics — $253M (latest: Series B)
  12. ProfoundBio — $250M (latest: Series B)
  13. Lycia Therapeutics — $232M (latest: Series D)
  14. Enliven Therapeutics — $230M (latest: Growth)
  15. Ray Therapeutics — $230M (latest: Series B)

Janus Henderson Investors Middle East Limited — related firms and companies (56)

Janus Henderson Investors Middle East Limited profile · All research reports